Other

Amgen misses 1Q views as higher costs cut profit

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Apr 22, 2014
popularity not rated yet | comments 0

Valeant, Ackman make $45.6B Allergan bid

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

Apr 22, 2014
popularity not rated yet | comments 0
  • Pages: 1